Will we recover, unbridle ourselves of debt, innovate, pay for our national security? Or, is China fated to become number one, leaving us to live in a Chinese world?

The best way to attract investment to the United States is not to penalize domestic firms that invest abroad, but to remove penalties on firms, domestic or foreign, that invest here. Numerous governments around the world have reached similar conclusions about their own economies and have reduced corporate income tax rates to attract investment to their shores.

Some consumers and businesses might see a little extra cash this summer as a result of the 2010 health care law. The Kaiser Family Foundation recently reported an estimated $1.3 billion in rebates will be delivered from health insurers who spent more than the law allotted on administrative expenses and profits.

The future is on the way.  Leading-edge innovators, we are assured, have already moved on, and are earnestly focusing on the just the sort of problems - manufacturing, energy, transportation (and I'd add healthcare) - that urgently require imaginative solutions.

In a recent letter, Martin Lobel describes as "intellectually bankrupt" our arguments against S. 940 and S. 2204, two recent bills that would have imposed unfavorable tax rules on five large oil companies that would not have applied to other taxpayers. Unfortunately, Lobel mischaracterizes our analysis of why the bills violate the rule of law.

With fakes of the cancer drug Avastin popping up in U.S. clinics in the past few months, patients are naturally worried about whether their medicines are safe.  Considering eighty percent of the ingredients in U.S. medicines come from overseas – mostly from China and India because their products are generally...

For several years now, President Obama and his allies in the environmental movement have promised to usher in a green economy that will create millions of new green jobs that “can’t be outsourced.”

American Enterprise Institute (AEI) economist  Roger Bate shares his expertise on counterfeit drug networks that pose a growing threat to combating diseases like malaria.